VIVUS (NASDAQ:VVUS) was upgraded by analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research note issued to investors on Friday.
Separately, Zacks Investment Research lowered shares of VIVUS from a “buy” rating to a “hold” rating in a report on Saturday, January 6th.
VIVUS (NASDAQ:VVUS) opened at $0.40 on Friday. The company has a current ratio of 7.47, a quick ratio of 7.09 and a debt-to-equity ratio of 643.86. VIVUS has a twelve month low of $0.40 and a twelve month high of $1.38. The company has a market cap of $42.81, a price-to-earnings ratio of 1.19 and a beta of 0.69.
A number of institutional investors have recently made changes to their positions in the business. OxFORD Asset Management LLP grew its holdings in VIVUS by 14.0% in the 3rd quarter. OxFORD Asset Management LLP now owns 1,059,382 shares of the biopharmaceutical company’s stock worth $1,040,000 after acquiring an additional 129,871 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in VIVUS by 166.2% in the 3rd quarter. Russell Investments Group Ltd. now owns 395,527 shares of the biopharmaceutical company’s stock worth $392,000 after acquiring an additional 246,927 shares during the last quarter. Creative Planning grew its holdings in VIVUS by 1,691.3% in the 4th quarter. Creative Planning now owns 366,706 shares of the biopharmaceutical company’s stock worth $184,000 after acquiring an additional 346,235 shares during the last quarter. Northern Trust Corp grew its holdings in VIVUS by 16.8% in the 2nd quarter. Northern Trust Corp now owns 275,097 shares of the biopharmaceutical company’s stock worth $335,000 after acquiring an additional 39,473 shares during the last quarter. Finally, Macquarie Group Ltd. bought a new stake in VIVUS in the 3rd quarter worth $192,000. 31.45% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “VIVUS (VVUS) Raised to Sell at ValuEngine” was posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2018/02/04/vivus-vvus-raised-to-sell-at-valuengine.html.
VIVUS, Inc is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED).
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for VIVUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS and related companies with MarketBeat.com's FREE daily email newsletter.